Accessibility Menu
Genetic Signatures logo

Genetic Signatures(ASX) GSS

Market CapA$13.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-88%
5 Year-96%
1 Year-82%
1 Month-8%
A$0.06
+1.72%
+0.00Today
Genetic Signatures last closing stock price
MetricPriceDate
Last closeAUD 0.062026-08-13
Genetic Signatures stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.062026-08-06
1 month-7.94%AUD 0.062026-07-14
3 month-24.68%AUD 0.082026-05-15
Year to date-76.8%AUD 0.252025-12-31
1 year-81.59%AUD 0.322025-08-13
3 year-89.91%AUD 0.582023-08-14
5 year-95.74%AUD 1.362021-08-13
Since inception-87.76%AUD 0.472015-03-31

Genetic Signatures Financials at a Glance

Market Cap

A$13.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$30.74M

Net Income (TTM)

-A$33.86M

EPS (TTM)

-A$0.05

P/E Ratio

-1.17

Dividend

A$0.00

Beta (Volatility)

0.07 (Low)

Price

A$0.06

Volume

313,193

Open

A$0.06

Previous Close

A$0.06

Daily Range

A$0.06 - A$0.06

52-Week Range

A$0.05 - A$0.43

Estimated Earnings Date

Aug 24, 2026

GSS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genetic Signatures

Genetic Signatures Limited is a molecular diagnostics company specializing in real-time Polymerase Chain Reaction (PCR)-based products for identifying infectious diseases. The company operates globally, providing innovative solutions to hospitals and laboratories through its proprietary MDx 3Base platform technology.

Products and Services
  • EasyScreen brand detection kits for various infectious diseases
  • MDx 3Base platform technology for comprehensive pathogen screening
  • Tailored detection kits for gastrointestinal, respiratory, and tropical diseases
Growth Outlook
  • Recent quarterly revenue reached AUD 8.68 million, indicating strong market demand
  • Expansion into new markets across the Asia Pacific and Americas enhances growth potential
  • Continued investment in R&D aims to innovate and diversify product offerings
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 30.5 million reflects a growing customer base
  • Current ratio of 8.99 indicates strong liquidity and financial health
  • Cash and short-term investments total AUD 29.87 million, providing operational flexibility
Genetic Signatures Limited is positioned in the healthcare sector, focusing on diagnostics and research. The company's innovative products cater to a wide range of infectious diseases, making it a key player in the molecular diagnostics market. With a solid financial foundation and a commitment to research and development, Genetic Signatures is poised for future growth. The recent quarterly performance demonstrates the company's ability to generate significant revenue, while its strong liquidity ratios suggest a robust operational capacity. As the demand for diagnostic solutions continues to rise globally, Genetic Signatures is well-equipped to capitalize on emerging opportunities in the healthcare landscape.
AI Generated • Jul 27, 2026

Industry

Life Sciences Tools and Services

CEO

Allison Rossiter

Headquarters

Newtown, NSW 2042, AU

GSS Financials

Key Financial Metrics (TTM)

Gross Margin

-80.05%

Operating Margin

-112.54%

Net Income Margin

-70.07%

Return on Equity

-23.93%

Return on Capital

-36.32%

Return on Assets

-22.98%

Earnings Yield

-85.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$13.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

227.14M

Volume

313.19K

Avg. Volume

516.28K

Financials (TTM)

Gross Profit

-A$16.08M

Operating Income

-A$34.98M

EBITDA

-A$32.35M

Operating Cash Flow

-A$20.30M

Capital Expenditure

-A$2.80M

Free Cash Flow

-A$23.10M

Cash & ST Invst.

A$29.87M

Total Debt

A$653.00K

Genetic Signatures Performance Analysis

Genetic Signatures annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 35,421,000N/A
20232023-06-30AUD 16,939,000-52.2%
20242024-06-30AUD 9,766,000-42.3%
20252025-06-30AUD 15,900,00062.8%
Genetic Signatures sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3071.0%
Q22024-12-3137.9%
Q42025-06-30-12.9%
Q22025-12-3117.3%
Genetic Signatures annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD 0.02N/A
20232023-06-30AUD -0.10N/A
20242024-06-30AUD -0.1113.0%
20252025-06-30AUD -0.09-17.9%
Genetic Signatures sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3051.7%
Q22024-12-31-95.5%
Q42025-06-3068.6%
Q22025-12-31-29.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$8.68M

+140.9%

Gross Profit

-A$6.61M

+30.0%

Gross Margin

-76.14%

N/A

Market Cap

A$13.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$112.60K

N/A

Employees

117

N/A

Net Income

-A$6.37M

+39.2%

EBITDA

-A$7.78M

+30.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$29.87M

+64.8%

Total Debt

A$653.00K

+5341.7%

Accounts Receivable

A$4.55M

+25.5%

Inventory

A$8.54M

+5.4%

Long Term Debt

A$188.00K

N/A

Short Term Debt

A$465.00K

+3775.0%

Return on Assets

-22.98%

N/A

Return on Invested Capital

-40.89%

N/A

Free Cash Flow

-A$948.00K

+83.4%

Operating Cash Flow

-A$349.00K

+85.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IPD.AXImpediMed Limited
A$0.01+20.00%
MX1.AXMicro-X Limited
A$0.03-3.45%
CYP.AXCynata Therapeutics Limited
A$0.01-0.00%
BMT.AXBeamtree Holdings Limited
A$0.11+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About GSS

What is the current price of Genetic Signatures?

Genetic Signatures is trading at A$0.06 per share.

What is the 52-week range for Genetic Signatures?

Over the past 52 weeks, Genetic Signatures has traded between A$0.05 and A$0.43.

How much debt does Genetic Signatures have?

As of the most recent reporting period, Genetic Signatures reported total debt of A$791.00K.

How much cash does Genetic Signatures have on hand?

Genetic Signatures reported A$7.47M in cash and cash equivalents in its most recent financial results.

What is Genetic Signatures’s dividend yield?

Genetic Signatures does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.